Glenbrook Capital Management increased its stake in SenesTech (NASDAQ:SNES). The investment manager purchased shares totaling $53,486 between May 14 and May 18, 2026, at prices ranging from $1.5878 to $1.7241 per share.
Following the transactions, Glenbrook's indirect ownership rose to 925,755 shares. The small-cap biotech firm has a market cap of $8.35 million, with shares trading at $1.59, down 40% over the past year.
Bond.az analysis suggests the stock is undervalued. Analysts have set a price target of $10.
SenesTech reported Q1 revenue of $493,000, up from $485,000, with a record gross margin of 68.6%.
